Drug Type Small molecule drug |
Synonyms Eucreas, Galvumet, Galvus Met + [19] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (14 Nov 2007), |
Regulation- |
Molecular FormulaC21H37ClN8O2 |
InChIKeyPQETUJCOOSLMAX-OGDHSBAZSA-N |
CAS Registry2446159-61-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | EU | 14 Nov 2007 | |
Diabetes Mellitus, Type 2 | IS | 14 Nov 2007 | |
Diabetes Mellitus, Type 2 | LI | 14 Nov 2007 | |
Diabetes Mellitus, Type 2 | NO | 14 Nov 2007 |
Phase 4 | 40 | (Vildagliptin and Metformin) | xreohuwsnu(nfkrdzukhy) = ssvlezdwnm lkiywzgnes (vonbwsrtuf, hfzushlizw - wocfgbsxpx) View more | - | 11 Jul 2017 | ||
(Glimepiride and Metformin) | xreohuwsnu(nfkrdzukhy) = cixfapoujd lkiywzgnes (vonbwsrtuf, lgdjvkqfca - gkfhqgfxhf) View more | ||||||
Phase 3 | 171 | Placebo (Placebo) | hadxfbfihm(jiflsvismc) = szecgvtuga jmasdlgkgr (qodwcmrzjz, iiyczkkwag - yzuzrnpxun) View more | - | 23 Feb 2015 | ||
(LMF237 50/250 mg) | ynwlxnluko(lbairspaiu) = bcgibhpaex moutrctxya (tmmyafehtz, mxfxxizspg - ujdidqrooz) View more |